Elicio's ELI-002 7P Shows Promising 'Priming' Effect in Pancreatic Cancer Combo
ELTX sits 50% above its 52-week low of $2.66.
Summary
Elicio Therapeutics presented new data showing preliminary complete responses in three metastatic mKRAS pancreatic cancer patients treated with ELI-002 7P followed by nivolumab-based checkpoint inhibitor therapy. This follows the June 15th news of ELI-002 7P failing its primary endpoint in a Phase 2 monotherapy study, and the June 17th 8-K which briefly mentioned these complete responses. The data is significant because these patients were typically unresponsive to checkpoint inhibitors, suggesting ELI-002 7P may have a 'priming effect'. This offers a potential new development strategy for a key asset after a recent setback, which is critical for the company given its 'going concern' warning. Elicio plans a staged Phase 1 program for the combination therapy, with rapid readouts expected within 3-6 months.
At the time of this announcement, ELTX was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $76M. The 52-week trading range was $2.66 to $16.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.